Jul 29, 2026 07:30AM
Jul 6, 2026 07:31AM
Jul 6, 2026 07:30AM
Jun 9, 2026 07:30AM
Jun 9, 2026 07:30AM
Jun 3, 2026 07:30AM
Jun 3, 2026 07:30AM TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
Jun 2, 2026 07:30AM
Jun 1, 2026 07:30AM
Jun 1, 2026 07:30AM
May 28, 2026 07:30AM
May 27, 2026 07:31AM
May 27, 2026 07:30AM
May 26, 2026 07:30AM TG Therapeutics presents BRIUMVI data at multiple sclerosis meeting
May 26, 2026 07:30AM
May 6, 2026 07:00AM
Apr 30, 2026 07:30AM
Apr 22, 2026 07:32AM
Apr 22, 2026 07:30AM
Apr 15, 2026 07:30AM
Apr 15, 2026 07:30AM TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Mar 19, 2026 07:30AM
Mar 19, 2026 07:30AM
Mar 9, 2026 07:31AM
Mar 9, 2026 07:30AM
Mar 6, 2026 07:31AM
Mar 6, 2026 07:30AM
Feb 26, 2026 07:00AM TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Feb 23, 2026 07:30AM
Feb 17, 2026 07:30AM
Feb 8, 2026 04:17PM
Feb 6, 2026 07:30AM
Feb 6, 2026 07:30AM
Jan 27, 2026 07:32AM
Jan 27, 2026 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Jan 13, 2026 04:25PM
Jan 13, 2026 04:25PM
Jan 7, 2026 07:30AM
Nov 28, 2025 07:30AM
Nov 19, 2025 08:30AM
Nov 10, 2025 04:00PM
Nov 3, 2025 07:00AM TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Oct 31, 2025 07:30AM
Oct 28, 2025 07:30AM
Oct 28, 2025 07:30AM
Sep 24, 2025 09:10AM
Sep 24, 2025 09:10AM
Sep 10, 2025 07:30AM
Sep 8, 2025 07:30AM TG Therapeutics begins phase 3 trial for subcutaneous BRIUMVI
Sep 8, 2025 07:30AM

1,173,798 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All